Source: Annals of oncology. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, METÁSTASE NEOPLÁSICA, RESULTADO DE TRATAMENTO, QUIMIOTERAPIA COMBINADA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BACHELOT, T et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, v. 30, n. 5, p. 766-773, 2019Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdz061. Acesso em: 14 out. 2024.APA
Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., et al. (2019). Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, 30( 5), 766-773. doi:10.1093/annonc/mdz061NLM
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2024 out. 14 ] Available from: https://doi.org/10.1093/annonc/mdz061Vancouver
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2024 out. 14 ] Available from: https://doi.org/10.1093/annonc/mdz061